Adenosine A1 receptor antagonists at a fork in the road.
Givertz
Michael M
MM
D058916:Adenosine A1 Receptor Antagonists; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006574:Heterocyclic Compounds, 2-Ring / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D007674:Kidney Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism; D043682:Receptor, Adenosine A1 / Q000378:metabolism; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects*
D058916:Adenosine A1 Receptor Antagonists; D002317:Cardiovascular Agents; D003510:Cyclohexanes; D004232:Diuretics; D006574:Heterocyclic Compounds, 2-Ring; D043682:Receptor, Adenosine A1; C523961:SLV320 compound